22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Recently Mexico has been facing a considerable and seemingly uncontrollable increase in femicide cas...
Read More >
Another Future of Work Hearing Scheduled. The House Higher Education and Workforce Development Subco...
Read More >
On May 15, 2020, in Geo-technology Associates Inc. v. Capital Station Dover, LLC, the Delaware Supre...
Read More >
Like many other state agencies, Texas stay-at-home orders issued in response to COVID-19 have shutte...
Read More >
In 2020, we will start to see private UK companies including the new corporate governance and report...
Read More >
The Ninth Circuit has ruled unanimously that privately operated internet platforms are “free to cen...
Read More >